3
Clinical Trials associated with SHR-2005 / Not yet recruitingPhase 1/2IIT Phase Ib/II Clinical Study of SHR-1501 Combined With SHR-2005 in the Treatment of Patients With High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC) which is not completely resectable by transurethral resection of bladder tumor (TURBt).
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate and high-risk non-muscle invasive bladder cancer.
SHR-2005膀胱灌注治疗中高危非肌层浸润性膀胱癌(NMIBC)的I期临床研究
[Translation] Phase I clinical study of SHR-2005 intravesical instillation for the treatment of intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC)
主要研究目的:评估SHR-2005膀胱灌注治疗中高危非肌层浸润性膀胱癌的安全性和耐受性,确定II期临床研究的推荐使用剂量(RP2D)。
次要研究目的:评估SHR-2005膀胱灌注的药代动力学(PK)和免疫原性;评估SHR-2005膀胱灌注治疗中高危NMIBC的初步疗效。
[Translation] Primary study objectives: To evaluate the safety and tolerability of intravesical instillation of SHR-2005 in the treatment of intermediate- and high-risk non-muscle invasive bladder cancer and determine the recommended dose (RP2D) for Phase II clinical studies.
Secondary study objectives: To evaluate the pharmacokinetics (PK) and immunogenicity of intravesical instillation of SHR-2005; to evaluate the preliminary efficacy of intravesical instillation of SHR-2005 in the treatment of intermediate- and high-risk NMIBC.
100 Clinical Results associated with SHR-2005
100 Translational Medicine associated with SHR-2005
100 Patents (Medical) associated with SHR-2005
100 Deals associated with SHR-2005